These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 7577347)

  • 21. Effectiveness of deferred therapy with ganciclovir in renal allograft recipients with cytomegalovirus disease.
    Waiser J; Budde K; Schreiber M; Korn K; Stenglein S; Drenckhahn JT; Böhler T; Hauser I; Neumayer HH
    Transplant Proc; 1998 Aug; 30(5):2083-5. PubMed ID: 9723399
    [No Abstract]   [Full Text] [Related]  

  • 22. Pre-emptive ganciclovir treatment can play a role in restoration of hematopoiesis after allogeneic bone marrow transplantation.
    Choi JH; Kim DW; Cho SG; Yoo JH; Jeong DC; Han CW; Shin WS; Min WS; Kim HK; Kim CC; Kim DJ
    Bone Marrow Transplant; 1997 Jan; 19(2):187-90. PubMed ID: 9116619
    [TBL] [Abstract][Full Text] [Related]  

  • 23. New immunosuppressive regimens and cytomegalovirus infection after kidney transplantation: a retrospective study.
    Côté I; Deschêsnes L; de Cotret PR; Lachance JG; Noël R; Isenring P; Houde I
    Transplant Proc; 2001; 33(7-8):3626-9. PubMed ID: 11750540
    [No Abstract]   [Full Text] [Related]  

  • 24. [Disease by CMV resistant to Ganciclovir. Should plasma valganciclovir levels be monitored in high risk patients?].
    Sola E; Vega E; Gutiérrez C; López V; Cabello M; Burgos D; González Molina M; Siles J
    Nefrologia; 2009; 29(2):180-1. PubMed ID: 19396331
    [No Abstract]   [Full Text] [Related]  

  • 25. Risk-adapted pre-emptive therapy for cytomegalovirus disease in patients undergoing allogeneic bone marrow transplantation.
    Mori T; Okamoto S; Matsuoka S; Yajima T; Wakui M; Watanabe R; Ishida A; Iwao Y; Mukai M; Hibi T; Ikeda Y
    Bone Marrow Transplant; 2000 Apr; 25(7):765-9. PubMed ID: 10745263
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Cytomegalovirus infection in patients after lung transplantation].
    Cerrina J; Le Roy Ladurie F
    Presse Med; 1992 Mar; 21(11):503-6. PubMed ID: 1315436
    [No Abstract]   [Full Text] [Related]  

  • 27. [Human cytomegalovirus infection].
    Tanaka-Taya K
    Nihon Rinsho; 2007 Feb; 65 Suppl 2 Pt. 1():136-40. PubMed ID: 17455606
    [No Abstract]   [Full Text] [Related]  

  • 28. Reassessing the impact of cytomegalovirus infection in kidney and kidney-pancreas transplantation.
    Becker BN; Becker YT; Leverson GE; Simmons WD; Sollinger HW; Pirsch JD
    Am J Kidney Dis; 2002 May; 39(5):1088-95. PubMed ID: 11979354
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Ganciclovir-resistant cytomegalovirus.
    Legendre C
    Lancet; 2000 Oct; 356(9238):1356. PubMed ID: 11073050
    [No Abstract]   [Full Text] [Related]  

  • 30. Prophylactic cytomegalovirus management strategies.
    Martin M
    Transplant Proc; 1995 Oct; 27(5 Suppl 1):23-7. PubMed ID: 7482812
    [No Abstract]   [Full Text] [Related]  

  • 31. Cytomegalovirus after heart transplantation: definitions for the guidance of antiviral therapy.
    Iberer F; Tscheliessnigg K; Halwachs G; Auer T; Wasler A; Petutschnigg B; Schreier G; Müller H; Allmayer T; Prenner G
    Scand J Infect Dis Suppl; 1995; 99():100-3. PubMed ID: 8668929
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prophylaxis of cytomegalovirus disease in allogeneic bone marrow transplantation.
    Grigg A; Phillips G
    J Infect Dis; 1992 May; 165(5):972-3. PubMed ID: 1314874
    [No Abstract]   [Full Text] [Related]  

  • 33. Pharmacoeconomic analysis of preemptive gancyclovir therapy in the prevention of cytomegalovirus infections in high-risk renal graft recipients.
    Chak WL; Choi KS; Wong KM; Chan YH; Chau KF; Li CS
    Transplant Proc; 2003 Feb; 35(1):280-1. PubMed ID: 12591399
    [No Abstract]   [Full Text] [Related]  

  • 34. Prevention and treatment of cytomegalovirus disease in thoracic organ transplant patients: evidence for a beneficial effect of hyperimmune globulin.
    Valantine HA
    Transplant Proc; 1995 Oct; 27(5 Suppl 1):49-57. PubMed ID: 7482821
    [No Abstract]   [Full Text] [Related]  

  • 35. Cytomegalovirus pneumonia after bone marrow transplantation successfully treated with the combination of ganciclovir and high-dose intravenous immune globulin.
    Emanuel D; Cunningham I; Jules-Elysee K; Brochstein JA; Kernan NA; Laver J; Stover D; White DA; Fels A; Polsky B
    Ann Intern Med; 1988 Nov; 109(10):777-82. PubMed ID: 2847609
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Late cytomegalovirus infection occurring two or more years following liver transplantation: a report of seven cases and review of the literature.
    Shibolet O; Ilan Y; Kalish Y; Safadi R; Ashur Y; Eid A; Shouval D; Wolf D
    Transplant Proc; 2003 Mar; 35(2):663-4. PubMed ID: 12644085
    [No Abstract]   [Full Text] [Related]  

  • 37. Marrow transplantation from unrelated volunteer donors.
    Anasetti C; Petersdorf EW; Martin PJ; Hansen JA
    Cancer Treat Res; 1995; 76():137-68. PubMed ID: 7577333
    [No Abstract]   [Full Text] [Related]  

  • 38. Kidney recipient CMV incidence in the gancyclovir era: monitoring viral DNA by a CMV-PCR assay.
    Cirocco RE; Ciancio G; Esquenazi V; Burke GW; Miller J
    Transplant Proc; 1999; 31(1-2):1362-3. PubMed ID: 10083604
    [No Abstract]   [Full Text] [Related]  

  • 39. Prevention of cytomegalovirus disease after heart transplantation: preemptive therapy with 7 days' intravenous ganciclovir.
    Paniagua MJ; Crespo-Leiro MG; De la Fuente L; Tabuyo T; Mosquera I; Cañizares A; Naya C; Fariña P; Juffé A; Castro-Beiras A
    Transplant Proc; 2002 Feb; 34(1):69-70. PubMed ID: 11959189
    [No Abstract]   [Full Text] [Related]  

  • 40. CD4(+) T-cell dynamics in primary cytomegalovirus infection.
    Rentenaar RJ; Gamadia LE; van der Hoek N; van Diepen FN; Boom R; Weel JF; van Lier RA; ten Berge IJ
    Transplant Proc; 2001 May; 33(3):2313-4. PubMed ID: 11377542
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.